-The Hindu Traders fix rates based on national online market NIZAMABAD (Telangana): The fall in turmeric price by over a half within a span of a month has left the farmers in distress. The joy of a bumper crop has been shortlived as the price, which varied between Rs. 8,200 and Rs. 7,500 per quintal a month ago now fell down between Rs. 4,000 and Rs. 5,000. The heavy variation in price is...
More »SEARCH RESULT
Total Matching Records found : 1516
Opposition criticises govt over 'agrarian crisis'
-PTI NEW DELHI: Opposition today came down hard on the government for the "agrarian crisis" and demanded waiver of loans of farmers across the country and not only of those from Uttar Pradesh as promised by Prime Minister Narendra Modi during campaigning. During a debate on Demand for Grants for the Agriculture Ministry in the Lok Sabha, members from opposition parties said over 12,000 farmers had committed suicide last year and asked...
More »How Assam's neglected black rice found a market in Delhi, Mumbai -Manjeet Sehgal
-India Today Commonly grown in Assam, the Black Rice (Kala chavul) is an exotic variety with amazing nutritional parameters like anti-oxidant, minerals, carbohydrates and fibre but the growers lacked the market. Chandigarh: The northeastern states like Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram and Sikkim are a veritable goldmine of organic foodgrains, herbs, spices and fruits. Despite the uniqueness and amazing health benefits, these foodgrains and herbs remain confined to these states as...
More »Agriculture: Here's why farmers are in trouble despite high pulse procurement
-The Financial Express Given the likely 22 million tonne production of pulses this year, up more than a third compared to last year, it is not surprising prices have crashed. In the case of tur, for instance, retail prices are down from R118 per kg in Delhi on October 1, 2016 to R89 on March 1. As a result of the surge in pulses inflation last year, rabi sowing increased by...
More »The high price of Big Pharma greed -Leena Menghaney
-The Hindu In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food & Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer. Roche effectively embroiled India’s...
More »
